Axsome Therapeutics
AXSM
41 hedge funds and large institutions have $41.6M invested in Axsome Therapeutics in 2016 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 14 increasing their positions, 6 reducing their positions, and 1 closing their positions.
500% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 1
133% more repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 6
14% more funds holding
Funds holding: 36 → 41 (+5)
0.73% less ownership
Funds ownership: 32.94% → 32.21% (-0.73%)
35% less capital inflows, than outflows
Capital inflows: $1.85M | Capital outflows: $2.85M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$596K |
| 2 |
BlackRock Fund Advisors
San Francisco,
California
|
+$399K |
| 3 |
Morgan Stanley
New York
|
+$199K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$130K |
| 5 |
BlackRock Institutional Trust
San Francisco,
California
|
+$89.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$2.19M |
| 2 |
Lombard Odier Asset Management (USA)
New York
|
-$548K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$104K |
| 4 |
BlackRock Advisors
Wilmington,
Delaware
|
-$4.35K |
| 5 |
BNP Paribas Financial Markets
Paris,
France
|
-$3.74K |
AXSM Hedge Fund Activity: Q4 2016 in Review
41 of the 4,008 institutional investors tracked by Wall St. Rank reported a position in Axsome Therapeutics (AXSM) for Q4 2016, worth a combined $41.6M — down 16% from $49.7M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new AXSM positions and 1 closed out — a net gain of 5 holders — while 14 added to existing stakes and 6 trimmed.
The largest buyer was Millennium Management, opening a new position worth an estimated $596K. The largest seller was Fidelity Investments, cutting an estimated $2.19M.
- 41 institutional investors held Axsome Therapeutics (AXSM) as of Q4 2016, up from 36 in Q3 2016.
- Funds reported $41.6M of Axsome Therapeutics stock for Q4 2016, down 16% quarter-over-quarter.
- 6 funds opened new Axsome Therapeutics positions in Q4 2016 and 1 closed out, a net change of +5 holders.
- The largest Axsome Therapeutics buyer in Q4 2016 was Millennium Management, an estimated $596K added.
- The largest Axsome Therapeutics seller in Q4 2016 was Fidelity Investments, an estimated $2.19M sold.
Based on aggregated 13F filings for Q4 2016.